Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janet Wittes

Showing results (61-70 of 122) with videos related to

Pageof 13
Sort By:
Clinical Trials (London, England)|November 11, 2005
Liability issues for data monitoring committee membersDavid L DeMets, Thomas R Fleming, Frank Rockhold, et al.
Statistics in Biopharmaceutical Research|May 26, 2025
Monitoring overall survival in pivotal trials in indolent cancersThomas R Fleming, Lisa V Hampson, Bharani Bharani-Dharan, et al.
Trials|October 18, 2022
Experiences of the Data Monitoring Committee for the RECOVERY trial, a large-scale adaptive platform randomised trial of treatments for patients hospitalised with COVID-19Peter A G Sandercock, Janet Darbyshire, David DeMets, et al.
Clinical Trials (London, England)|April 1, 2025
Response to Cleland and AnzarJanet Wittes, David L DeMets, KyungMann Kim, et al.
Clinical Trials (London, England)|April 1, 2025
Aspirin in primary prevention: Undue reliance on an uninformative trial led to misinformed clinical guidelinesJanet Wittes, David L DeMets, KyungMann Kim, et al.
Annals of Internal Medicine|June 9, 2015
Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority StudiesHajime Uno, Janet Wittes, Haoda Fu, et al.
Human Vaccines|October 13, 2006
Preclinical evaluation of a chimeric malaria vaccine candidate in Montanide ISA 720: immunogenicity and safety in rhesus macaquesJan A M Langermans, Meike Hensmann, Marcel van Gijlswiik, et al.
The New England Journal of Medicine|February 17, 2005
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma preventionScott D Solomon, John J V McMurray, Marc A Pfeffer, et al.
The New England Journal of Medicine|November 22, 2014
Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitorsMatthew R Weir, George L Bakris, David A Bushinsky, et al.
Archives of Internal Medicine|February 13, 2002
Cost-effectiveness of gemfibrozil for coronary heart disease patients with low levels of high-density lipoprotein cholesterol: the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention TrialJohn A Nyman, Melissa S Martinson, David Nelson, et al.
Pageof 13

Showing results (61-70 of 122) with videos related to

Sort By:
Pageof 13
Clinical Trials (London, England)|November 11, 2005
Liability issues for data monitoring committee membersDavid L DeMets, Thomas R Fleming, Frank Rockhold, et al.
Statistics in Biopharmaceutical Research|May 26, 2025
Monitoring overall survival in pivotal trials in indolent cancersThomas R Fleming, Lisa V Hampson, Bharani Bharani-Dharan, et al.
Trials|October 18, 2022
Experiences of the Data Monitoring Committee for the RECOVERY trial, a large-scale adaptive platform randomised trial of treatments for patients hospitalised with COVID-19Peter A G Sandercock, Janet Darbyshire, David DeMets, et al.
Clinical Trials (London, England)|April 1, 2025
Response to Cleland and AnzarJanet Wittes, David L DeMets, KyungMann Kim, et al.
Clinical Trials (London, England)|April 1, 2025
Aspirin in primary prevention: Undue reliance on an uninformative trial led to misinformed clinical guidelinesJanet Wittes, David L DeMets, KyungMann Kim, et al.
Annals of Internal Medicine|June 9, 2015
Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority StudiesHajime Uno, Janet Wittes, Haoda Fu, et al.
Human Vaccines|October 13, 2006
Preclinical evaluation of a chimeric malaria vaccine candidate in Montanide ISA 720: immunogenicity and safety in rhesus macaquesJan A M Langermans, Meike Hensmann, Marcel van Gijlswiik, et al.
The New England Journal of Medicine|February 17, 2005
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma preventionScott D Solomon, John J V McMurray, Marc A Pfeffer, et al.
The New England Journal of Medicine|November 22, 2014
Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitorsMatthew R Weir, George L Bakris, David A Bushinsky, et al.
Archives of Internal Medicine|February 13, 2002
Cost-effectiveness of gemfibrozil for coronary heart disease patients with low levels of high-density lipoprotein cholesterol: the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention TrialJohn A Nyman, Melissa S Martinson, David Nelson, et al.
Pageof 13